Sunjong Kwon

I received my Ph.D. from the University of Connecticut Health Center, USA and worked as a postdoctoral fellow at Harvard Medical school, USA. I then served on the faculty position at Oregon Health & Science University, USA for 21 years. Since 2022, I joined to EyeGene Inc., Republic of Korea and I am currently leading the R&D of the ischemic disease therapeutics, recombinant protein vaccines, and mRNA vaccines. We are planning phase 2 clinical trial for “EG-Mirotin”, a Non-proliferative diabetic retinopathy (NPDR) therapeutics and we have developed a shingles vaccine “EG-HZ” and completed phase 1 clinical trial, confirming safety and efficacy. We have plans for next clinical trials of EG-HZ. As for the COVID-19 mRNA vaccine, we have been developing “EG-COVID” for WT and “EG-COVARo” for Omicron, and clinical trials related to boosting vaccinations are in progress. Also, bivalent COVID-19 mRNA vaccine, combining EG-COVID and EG-COVARo, is under development.